A ONE-WAY DRUG DRUG INTERACTION STUDY TO ASSESS THE EFFECT OF EFAVIRENZ ON THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF BMS-790052 IN HEALTHY SUBJECTS

Completed

• Conditions: Hepatitis C; viral liver inflammation; 10047438

• Registration Number: NL-OMON36747
• Lead Sponsor: Bristol-Myers Squibb

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 17

Inclusion Criteria

Age: 18-49 years, inclusive
BMI: 18.0 - 32.0 kg/m2, inclusive
Females should be post menopausal or surgically sterile

Exclusion Criteria

Suffering from: hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 90 days from the start of the study or in case of donating more than 1 liter of blood (men) or more than 1.5 liter of blood (women) in the 10 months prior the start of this study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- Pharmacokinetics<br /><br>- Safety</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>N.a.</p><br>